Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-K stay in one workspace.
VVOS
$0.15
-1.76%
VVOS
· Vivos Therapeutics, Inc.
$0.15
0.00 (-1.76%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of June 30, 2026, we had approximately $1.8 million in cash and cash equivalents, which will not be sufficient to fund operations and strategic objectives over the next twelve months from the date of the issuance of these financial statements. Without additional financing, these factors raise substantial doubt regarding the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$2.83M
Shares
20.12M
Volume · Oct 7
419.75K
Avg daily vol (3M)
12.36M
All webcasts
Earnings call · FY2024 Q4
Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Revenue · derived Q4
$3.70M
+13.9% YoY
Gross margin · derived Q4
56.7%
-7.6 pp YoY
Net income · derived Q4
-$2.83M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Mar 31, 2025 · complete as-filed document
SEC periodic report
10-K report
Filed Mar 31, 2025 · complete as-filed document